NEW ORLEANS — Empagliflozin, an SGLT2 inhibitor, used in addition to standard of care reduced the risk for composite microvascular outcomes in patients with type 2 diabetes and high CV risk, Nestoras N. Mathioudakis, MD, MHS, the clinical director of the division of endocrinology, diabetes and metabolism at Johns Hopkins University, told Endocrine Today.
“What was found was that in a composite of microvascular outcomes, empagliflozin (Jardiance, Boehringer Ingelheim) actually reduces microvascular outcomes by 40%, but interestingly that risk reduction seems to be driven predominantly by nephropathy,” Mathioudakis said.
In this video — the second in a series that discusses the risks and benefits of SGLT2 inhibitors in patients with type 1 and type 2 diabetes — Mathioudakis highlights updated results from the EMPA-REG Outcome study that Christoph Wanner, MD, and colleagues, presented at the American Diabetes Association Scientific Sessions.
Mathioudakis also discusses data that demonstrated that dapagliflozin (Farxiga, AstraZeneca) appeared to have favorable micro- and macrovascular effects at 6-week follow-up.
However, Mathioudakis mentions that the positive results do not reflect all patients with type 2 diabetes.
“The one thing that I want to point out … is that this class effect is really in [a] group of patients with established cardiovascular disease rather than new-onset patients with type 2 diabetes,” he said. Whether we can generalize about an SGLT2 cardioprotective effect — for all patients with type 2 diabetes — I think remains to be seen.”